论文部分内容阅读
目的：探讨肺转移瘤外科治疗的指征、术前评价、手术方法及影响预后的因素。方法：对１０６ 例肺转移瘤的临床资料进行回顾性分析。结果：经手术治疗的肺转移瘤１０６ 例，其中转移性癌８６ 例，转移性肉瘤２０ 例，二者５ 年生存率分别为１９ ．８％ 和２０％ 。以原发肿瘤乳腺癌、头颈部癌、泌尿系癌及骨肉瘤的肺转移预后较好，５ 年生存率分别为３３ ．３ ％ 、２７ ．３ ％ 、２０ ％ 及３３ ．３ ％ 。全组１ 年、３ 年、５ 年和１０ 年生存率分别为８３ ％ 、３５ ．８ ％ 、９．８ ％ 和６ ．６ ％ 。术后行跟放／ 化疗者的５ 年生存率为１８ ．１ ％ ，未行者２３ ．５ ％ ，二者间差异不显著。全组并发症的发生率为４．２ ％ ，无手术死亡。结论：对原发肿瘤已达根治，无他处转移及肺功能可承受手术者作为手术指征；手术途径以病侧后外切口为主；探查时应避免遗漏多发转移灶，遵循最大限度切除肺转移瘤及保留正常肺组织的原则；重视前瞻性的术后辅助治疗，以期提高手术疗效。
Objective: To investigate the indications for surgical treatment of pulmonary metastases, preoperative evaluation, surgical methods, and factors influencing prognosis. Methods: The clinical data of 106 cases of lung metastases were retrospectively analyzed. Results: Of the 106 lung metastatic tumors treated with surgery, 86 were metastatic carcinomas and 20 were metastatic sarcomas. The 5-year survival rate was 19%. 8% and 20%. The prognosis of lung metastases with primary tumors of breast, head and neck, urinary tract, and osteosarcoma was better, with a 5-year survival rate of 33%. 3%, 27 . 3%, 20% and 33. 3%. The 1-, 3-, 5-, and 10-year survival rates for the whole group were 83% and 35, respectively. 8 %, 9.8%, and 6. 6 %. The 5-year survival rate of patients who underwent postoperative radiotherapy and chemotherapy was 18%. 1 %, not 23. 5 %, the difference between the two is not significant. The incidence of complications in the whole group was 4.2%, and no operative death occurred. Conclusion: The primary tumor has reached a radical treatment, no other metastasis and pulmonary function can withstand the operation as an indication for surgery; surgical approach to the disease side of the main external incision; exploration should avoid multiple missed metastases, follow the maximum removal Pulmonary metastases and retention of normal lung tissue principles; emphasis on prospective postoperative adjuvant therapy in order to improve the efficacy of surgery.